来自伊朗遗传性结直肠癌登记册的患者的生殖系变异
Lena Goshayeshi1,2, Saeed Hoorang3, Benyamin Hoseini4
1Surgical Oncology Research Center, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Cancer cell international
|April 13, 2025
概括
这项研究确定了伊朗遗传性结直肠癌 (CRC) 中的关键生殖系变异. 建议进行基因检测和级联查,以早期诊断和管理遗传性CRC综合征.
科学领域:
- 遗传学 遗传学是一种遗传学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 遗传性癌症综合征导致6-10%的结直肠癌 (CRC) 病例.
- 鉴定生殖系变异对于遗传检测,咨询和监测至关重要.
- 这项研究侧重于伊朗人口,以确定遗传性CRC生殖系变异的流行率.
研究的目的:
- 在伊朗人口中确定与遗传性结直肠癌相关的生殖系变异的流行率.
- 识别影响遗传检测和患者管理的新型致病变体.
- 分析基因本体学和蛋白质-蛋白质相互作用,以更深入地了解CRC中的基因功能.
主要方法:
- 整体外基因组测序 (WES) 在101名来自伊朗遗传性结肠直肠癌注册表 (IHCCR) 的患者身上进行.
- 该队列包括63名高风险林奇综合征 (LS) 患者和38名结直肠多重症患者.
- 进行了生殖系变异,表型谱,基因本体学和蛋白质-蛋白质相互作用 (PPI) 分析.
主要成果:
- 致病性/可能致病性 (P/LP) 变体在36.51%的Lynch相关基因患者中被发现.
- 在26.98%的患者中发现了非林奇基因的P/LP变异 (例如TP53,ATM).
- 在多发症患者中,在APC (50%) 和MUTYH (15.79%) 中发现了显著的P/LP变异;级联测试确定了50%的亲属.
结论:
- 在伊朗人群中发现了遗传多重症和非多重症CRC的关键生殖系变异.
- 为诊断遗传性结直肠癌综合征,建议采用选择性策略和级联基因测试.
- 这些发现支持针对性基因查和改善遗传性CRC的管理协议.
相关概念视频
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...